New treatments for lung fibrosis using FAK inhibitors
Official title: Non-catalytic FAK inhibitors as novel therapeutics for lung fibrosis
Funded at Faknostics, LLC · NIH-11008778 · Data updated 2026-11-12
This study is exploring new treatments for idiopathic pulmonary fibrosis (IPF) by targeting a protein that contributes to lung scarring, with the hope of helping patients breathe better and feel healthier.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Faknostics, LLC NIH-funded |
| Lab location | 1 site (Phoenix, United States) |
| Project start | August 10, 2022 |
| Project end | July 31, 2027 |
| Funding year | 2024 |
| Award (this year) | $673,796 |
| NIH project number | 2R42HL162392-02 |
| Project ID | NIH-11008778 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with idiopathic pulmonary fibrosis or related fibrotic lung disorders.
✕Less likely to help
Patients with other types of lung diseases or those who do not have a diagnosis of fibrosis may not benefit from this research.
What this research studies
This research focuses on developing novel therapies for idiopathic pulmonary fibrosis (IPF), a serious lung condition that leads to progressive scarring of lung tissue. The approach involves targeting a protein called Focal Adhesion Kinase (FAK), which plays a key role in the development of fibrosis by influencing cell behavior and the secretion of fibrotic proteins. By inhibiting FAK, the research aims to reduce fibrosis and improve lung function in affected patients. The study will involve laboratory experiments and potentially clinical trials to assess the effectiveness of these inhibitors.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for lung fibrosis, improving patient outcomes and quality of life.
How similar studies have gone: While there have been some successes in targeting FAK in other conditions, this specific approach for lung fibrosis is relatively novel and has not been extensively tested.
Where this research is happening
-
Faknostics, LLC
Phoenix, United States Active
Researchers
- Principal investigator: Marlowe, Timothy a — Faknostics, LLC
- Study coordinator: Marlowe, Timothy a
Related research
Other NIH-funded projects on the same topics.
-
Interface between immune cells and scarring in the eye
This grant looks at how immune cells influence scar formation in the cornea after injury and how this affects vision.
-
How often to treat schistosomiasis to protect the liver
A randomized trial will test different frequencies ofPraziquantel treatment to prevent liver damage in people aged 15–40 with schistosomiasis in Uganda.
-
Metabolic changes in cells that repair blood vessels in the eye lens to prevent scarring
A drug or approach that changes how certain cells that repair blood vessels in the eye work, to prevent scarring behind the retina in age-related macular degeneration patients treated with anti-VEGF therapy.
-
Myocardial fibrosis and fat in ART-treated women with HIV in sub-Saharan Africa
This project studies heart tissue changes in women with HIV in sub-Saharan Africa who are on antiretroviral therapy, to understand why they’re at higher risk for heart problems as they age.
-
Myocardial fibrosis and fat in ART-treated women with HIV in sub-Saharan Africa
This grant studies heart tissue changes in women living with HIV in sub-Saharan Africa to understand why heart failure risk is higher in this group.
-
Molecular clues to progressive lung scarring
Researchers are studying how lung tissue becomes progressively scarred, focusing on cell signals and receptors that may drive fibrosis in people with lung disease.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.